Last reviewed · How we verify
PRAX-222 - Initial Dose
At a glance
| Generic name | PRAX-222 - Initial Dose |
|---|---|
| Sponsor | Praxis Precision Medicines |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRAX-222 - Initial Dose CI brief — competitive landscape report
- PRAX-222 - Initial Dose updates RSS · CI watch RSS
- Praxis Precision Medicines portfolio CI